Oncopro Hereditary Cancer Risk Panel Screens 200 Genes Test Price 2400 AED
Unraveling Your Cancer Risk: A Look at the Oncopro Hereditary Cancer Risk Panel (200 Genes) Test in the UAE
Cancer remains a top health issue globally, and while certain risk factors are well-known, genetics can also have a substantial impact. If you’re in the UAE and worried about your genetic predisposition to cancer, the Oncopro Hereditary Cancer Risk Panel (200 Genes) Test could be an essential resource for obtaining crucial insights.
Deciphering Hereditary Cancer Risk
Specific gene mutations can heighten your risk of developing particular cancers. These mutations can be passed down from a parent to their children. The Oncopro Hereditary Cancer Risk Panel Test is designed to detect such mutations across a wide array of genes.
How Does the Oncopro Hereditary Cancer Risk Panel (200 Genes) Test Function?
This test employs advanced next-generation sequencing (NGS) technology to scrutinize the DNA in a blood sample. Here’s an outline of the procedure:
Comprehensive Gene Analysis: The test concurrently investigates an extensive panel of 200 genes associated with diverse hereditary cancer types, including breast cancer, colon cancer, and ovarian cancer. Mutation Identification: The test diligently looks for mutations within these genes that could potentially heighten your cancer risk.
Advantages of the Oncopro Hereditary Cancer Risk Panel (200 Genes) Test:
Prompt Detection: A positive test result can pinpoint an elevated risk for specific cancers. This enables the implementation of early detection strategies like regular screenings, potentially leading to prompt diagnosis and treatment. Risk Categorization: The test results can assist doctors in classifying your overall risk level for developing various cancers. This personalized data allows for a more customized approach to preventive measures. Informed Choices: Being aware of your genetic predisposition enables you and your doctor to make knowledgeable decisions about preventive measures and cancer screening plans. This proactive approach can significantly enhance your long-term health outcomes. Family Planning: If you have a family history of cancer, the test results can be useful for genetic counseling discussions before starting a family. Comprehending your risk allows for informed decisions regarding cancer screening and potential pre-implantation genetic diagnosis (PGD).
Who Can Gain from the Oncopro Hereditary Cancer Risk Panel (200 Genes) Test?
This test is particularly advantageous for individuals with:
A personal history of cancer, especially if diagnosed at a young age. A robust family history of cancer, particularly in multiple blood relatives on the same side of the family. Worries about their hereditary cancer risk due to ethnicity or ancestry. Certain populations have a higher prevalence of specific cancer-associated mutations.
What to Anticipate During the Test?
The Oncopro Hereditary Cancer Risk Panel (200 Genes) Test typically involves a straightforward blood draw from your arm. There’s no special preparation required, although your doctor might advise you to temporarily stop certain medications that could affect the test results.
Important Considerations:
The cost of the test can fluctuate depending on the healthcare facility you visit in the UAE. A positive test result signifies an increased risk, but it doesn’t guarantee you will develop cancer. It’s vital to understand this distinction and discuss the implications with a genetic counselor. Genetic counseling before and after the test is strongly recommended. A genetic counselor can clarify the test results in detail, address any concerns you may have, and guide you through the next steps based on your specific situation.
Proactively Managing Your Health
If you’re worried about your hereditary cancer risk, discussing the Oncopro Hereditary Cancer Risk Panel (200 Genes) Test with your doctor in the UAE can be a critical step towards proactive healthcare. Early detection and preventive measures can significantly enhance your cancer outcomes.
At DNA Labs UAE, we offer the ONCOPRO HEREDITARY CANCER RISK PANEL Screens 200 Genes Test. This genetic test screens for mutations in 200 genes that are associated with an increased risk of developing certain types of cancer.
Test Details
The ONCOPRO HEREDITARY CANCER RISK PANEL is a powerful tool for identifying individuals at an increased risk of developing cancer. The test analyzes DNA samples from a patient’s blood or saliva to detect mutations that may increase their risk of developing cancer. It screens for mutations in genes associated with a wide range of cancers, including breast, ovarian, colorectal, pancreatic, and prostate cancer, among others.
Benefits of the Test
The ONCOPRO HEREDITARY CANCER RISK PANEL allows for earlier detection of cancer and potentially life-saving interventions. By identifying individuals who may have an inherited predisposition to cancer, personalized prevention and treatment strategies can be developed. The test can also inform cancer treatment decisions, as certain genetic mutations may affect how a patient responds to certain therapies.
Test Cost
The cost of the ONCOPRO HEREDITARY CANCER RISK PANEL Screens 200 Genes Test is AED 2400.
Symptoms and Diagnosis
Individuals who may benefit from this test include those with a personal or family history of cancer, as well as those who have certain genetic syndromes that increase their risk of developing cancer. If you experience any symptoms associated with cancer or have concerns about your risk, it is important to consult with an oncologist for further evaluation and guidance.
Sample Collection and Delivery
A 10 mL (8 mL min.) whole blood sample is required for the test. The sample should be collected in 1 Lavender Top (EDTA) tube and shipped immediately at 18-22°C. It is important not to refrigerate or freeze the sample. The test results will be delivered within 35 working days.
Pre-Test Information
Before undergoing the ONCOPRO HEREDITARY CANCER RISK PANEL Screens 200 Genes Test, it is mandatory to fill out the Oncopro Hereditary Cancer Risk Clinical Information Form (Form 27).
Method and Test Type
The ONCOPRO HEREDITARY CANCER RISK PANEL Screens 200 Genes Test is performed using Next Generation Sequencing. It falls under the category of molecular diagnostics and is specifically designed to detect cancer-related genetic mutations.
Conclusion
The ONCOPRO HEREDITARY CANCER RISK PANEL Screens 200 Genes Test offered by DNA Labs UAE is a comprehensive and advanced genetic test that can identify individuals at an increased risk of developing cancer. By providing early detection and personalized treatment strategies, this test can play a crucial role in saving lives and improving patient outcomes.
| Test Name | ONCOPRO HEREDITARY CANCER RISK PANEL Screens 200 Genes Test |
|---|---|
| Components | AIP CBL CYLD EXT2 GNAII MEN1 NTRK2 PTPN11 SAMD9L STAT3 ALK CD70 DDB2 EZH2 GPC3 MET NTRK3 PTPN13 SBDS STK11 ANKRD26 CD82 DDX41 FAM111B GPR101 MITF PALB2 RAD50 SDHA SUFU AP2S1 CDC73 DICER1 FAM175A GREM1 MLH1 PALLD RAD51C SDHAF2 TERT APC CDH1 DIS3L2 FANCA HNF1A MLH3 PAX5 RAD51D SDHB TGFBR2 APOBEC3B CDH10 DKC1 FANCB HNF1B MPL PDGFRA RAF1 SDHC TINF2 AR CDK4 EFNA1 FANCC HOXB13 MRE11A PHOX2B RASA2 SDHD TMEM127 ATM CDKN1A EGFR FANCD2 HRAS MSH2 PMS1 RB1 SETBP1 TP53 ATR CDKN1B ELAC2 FANCE IKZF1 MSH3 PMS2 RECQL SHOC2 TP63 AXIN2 CDKN1C ELANE FANCF KDR MSH6 POLD1 RECQL4 SLX4 TSC1 BAP1 CDKN2A ENG FANCG KIF1B MSR1 POLE REST SMAD4 TSC2 BARD1 CDKN2B EPCAM FANCI KIT MUTYH POLH RET SMARCA4 VHL BLM CDKN2C ERCC1 FANCL KITLG NBN POLQ RHBDF2 SMARCB1 WRN BMPR1A CEBPA ERCC2 FANCM KRAS NF1 POT1 RIT1 SMARCE1 WT1 BRAF CEP57 ERCC3 FEN1 LMO1 NF2 PPM1D RNASEL SOS1 XPA BRCA1 CFTR ERCC4 FH LZTR1 NRAS PRF1 RNF43 SOS2 XPC BRCA2 CHEK2 ERCC5 FLCN MAP2K1 NSD1 PRKAR1A RPS20 SPINK1 XRCC2 BRIP1 CRTAC1 ETV6 GALNT12 MAP2K2 NSUN2 PRSS1 RRAS SPOP XRCC3 BUB1B CTNNA1 EXO1 GATA2 MAX NTHL1 PTCH1 RUNX1 SPRED1 CD82 CASR CTRC EXT1 GCM2 MC1R NTRK1 PTEN SAMD9 SRP72 MXI1 |
| Price | 2400 AED |
| Sample Condition | 10 mL (8 mL min.) whole bloodin 1 Lavender Top (EDTA) tube. Ship immediately at 18\u0192??22?\u00f8C. DO NOT REFRIGERATE OR FREEZE. Duly filled Oncopro Hereditary Cancer Risk Clinical Information Form (Form 27) is mandatory. |
| Report Delivery | Sample Daily by 9 am; Report 35 Working days |
| Method | Next Generation Sequencing |
| Test type | Cancer |
| Doctor | Oncologist |
| Test Department: | MOLECULAR DIAGNOSTICS |
| Pre Test Information | Duly filled Oncopro Hereditary Cancer Risk Clinical Information Form (Form 27) is mandatory. |
| Test Details | The Oncopro Hereditary Cancer Risk Panel is a genetic test that screens for mutations in 200 genes that are associated with an increased risk of developing certain types of cancer. The test is designed to identify individuals who may have an inherited predisposition to cancer, allowing for earlier detection and potentially life-saving interventions.The panel includes genes associated with a wide range of cancers, including breast, ovarian, colorectal, pancreatic, and prostate cancer, among others. The test analyzes DNA samples from a patient’s blood or saliva to detect mutations that may increase their risk of developing cancer.The Oncopro Hereditary Cancer Risk Panel is typically recommended for individuals with a personal or family history of cancer, as well as those who have certain genetic syndromes that increase their risk of developing cancer. The test can also be used to inform cancer treatment decisions, as certain genetic mutations may affect how a patient responds to certain therapies.
Overall, the Oncopro Hereditary Cancer Risk Panel is a powerful tool for identifying individuals at increased risk of developing cancer and guiding personalized cancer prevention and treatment strategies. |
